cyrilzakka/clinical-trials huggingface dataset:
Referral to Pharmacists - Ambulance Clinician Experience Survey

Falls in people aged 65 years and over are a common reason for calling the emergency ambulance service. Falls can be serious, with about 1 in 20 people having to be taken to hospital because they have been injured. Thankfully, in more than 4 out of 10 cases, people are not seriously injured and can be left at home. However, it is important that the reason for the fall is found and future falls are prevented where possible.

Yorkshire Ambulance Service can already make a referral to another local service to get specialist practical help for falls prevention when people are left at home after a fall. Research has shown that the safe use of medicines can prevent future falls, but that did not form. Now a new service has been set up for Yorkshire Ambulance Service to refer patients to the Leeds General Practice (GP) Confederation. A pharmacist working in the patients GP surgery will undertake a review of the patient's use of their medicines.

However, it is unknown how ambulance staff identify patients who may be at risk of future falls due to medicines being taken or issues with medicines management at home. This data is not currently collected in any ambulance patient records. It is also not known what their current practice is when a patient who is not managing their medicines well is identified. A literature search has revealed no papers on this topic. This research survey seeks to understand how ambulance clinicians identify and assist patients who are having difficulty in managing their medicines. Therefore, the results of this study are likely to provide new knowledge which will be generalisable to United Kingdom (UK) ambulance service practice.


Eligibility Criteria:
Inclusion Criteria:

* Clinical staff working operationally, providing frontline ambulance care in Yorkshire Ambulance Service National Health Service (NHS) Trust during the PREFACES project (24th May, 2019 to 31st May 2020)

Exclusion Criteria:

* Clinical staff NOT working operationally, providing frontline ambulance care in Yorkshire Ambulance Service NHS Trust
* Non-clinical staff
Effects of Core Stability Training on Gait in Multiple Sclerosis Patients

Gait and mobility are among the functions frequently affected in Multiple Sclerosis (MS) and have a negative impact on quality of life. Strength losses in lower limb muscles, ataxia, sensory problems and fatigue are the most important reasons of walking problems in patients with MS. In addition to loss of strength and tonus problems, especially biomechanical disorders can be seen on foot and this problem affects gatin and balance negatively. The stabilizing muscles, defined as the "core" region and enveloping the body like a corset, are active in the context of postural preparation prior to lower extremity movements and stabilize for the limb movements to be performed. The aim of this study was to investigate the effects of spinal stabilization exercises on walking performance, fatigue, plantar pressure distribution, balance, muscle strength and quality of life in patients with Multiple Sclerosis.


Eligibility Criteria:
Inclusion Criteria:

* Older than 18 years old
* EDSS score is between 3-5,5
* Patients who did not take corticosteroid therapy within three months
* Patients who get at least 24 points from the Mini Mental Test were included in the study.

Exclusion Criteria:

* Patients who had an acute MS attack or had an attack within the last three months.
* An orthopedic or systemic problem that would prevent participation in exercises
* Patients who were using walking orthoses or walking aids were not included in the study.
Intestinal Microbiota in Stem Cell Transplant Transplant Admission

In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.

Early preclinical studies suggested that intestinal microflora contribute to aGVHD and may be relapse. There is increasing evidence that use of antibiotics may have a detrimental impact on intestinal microbiota composition and, consequently, the outcome of SCT.However, effect on different antibiotic prophylaxis regimens and broad-spectrum antibiotics used during transplant and the intestinal microbiota composition and hence adverse outcomes are not known. Stool samples will be collected from patients who are undergoing SCT at:

1. preconditioning
2. at day 0 (stem cell infusion)
3. once in the period of day + 7-10 post SCT
4. once first day or second day of BMT OPD clinic visit
5. once if they develop \>=grade I GVHD
6. once at time of recovery from GVHD

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-80 years
* patients undergoing allogenic or autologous SCT for malignant hematological conditions or bone marrow failure
Detecting Lesions in the Oral Cavity With Thermal Imaging

Previous studies indicate that there are significant differences in the temperature of tumors and normal, adjacent tissues. The present study will test this hypothesis for lesions in the oral cavity. Thermal images of the oral cavities of patients, undergoing examination in the Department of Oral and Maxillofacial Surgery of Sheba hospital, will be compared to the diagnoses of the examining doctors. The results, apart from enhancing the delineation of oral cavity tumors, may help the decision to develop miniature thermal cameras to scan thermally, the GI tract.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed in the Department of Oral and Maxillofacial Surgery as suffering from malignant or possibly malignant lesions.

Exclusion Criteria:

* none
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer

Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The investigators assess first, the incidence of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma viral oncogene homolog (KRAS) mutations, SOS and hepatocyte growth factor (HGF) expression, anaplastic lymphoma kinase (ALK) translocation and expression and, secondly, the investigators correlate molecular markers with clinical features and outcome in terms of response rate, progression free survival and overall survival.

Non small cell lung cancer patients.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with available tumor tissue for mutational analysis
* Metastatic disease treated with gefitinib or erlotinib
* Presence of at least one measurable lesion according to RECIST criteria

Exclusion Criteria:

* No tumor tissue available
* No clinical data available
Effect of Freezing Phenomenon in Patients With Parkinson's Disease

Although the literature review indicates that plantar pressure may be related to freezing, there are not enough studies examining the effect of freezing phenomenon on pedobarographic pressure distribution and gait parameters. Therefore, the aim of our study is to examine the effect of freezing phenomenon on gait parameters and pedobarographic pressure distribution in patients with Parkinson's Disease.

Individuals diagnosed with Idiopathic Parkinson's disease by a physician and healthy individuals with similar demographic characteristics will be included in the study. Individuals will be examined in 3 groups: a group of patients with Parkinson's Disease with freezing phenomenon, a group of patients with Parkinson's Disease without freezing phenomenon, and a healthy control group.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study
* Being between stage 2-3 according to the Modified Hoehn-Yahr Staging Scale
* Having a score of 24 or above from the Standardized Mini Mental Test

Exclusion Criteria:

* Presence of an additional neurological or psychiatric disease other than Parkinson's disease
* Presence of uncontrollable dyskinesia or motor fluctuations
* Presence of postural hypotension, vision problems (that cannot be compensated with the correct lens) or vestibular disorders that may affect balance
* Presence of cardiopulmonary diseases that may affect walking
* Presence of orthopedic problems and inflammatory arthritis (such as fractures, osteoporosis, osteomyelitis) that may cause limitation of movement and affect gait and evaluations
VentilO Prospective Study

This is a randomized, open-label study comparing intial settings made by clinicians with settings recommandation made by the VentilO application immediately after intensive care unit admission.The study will allow direct comparison of the frequency of acidosis when patients are ventilated using the parameters of the VentilO application versus parameters chosen by the clinician. The variables determined by the clinician or VentilO will be respiratory rate, tidal volume and resulting minute ventilation.


Eligibility Criteria:
Inclusion Criteria:

* Adults (\> 18 years old)
* Intubated patients admitted to intensive care immediately post-operatively after cardiac surgery (all cardiac surgery combined)
* Ventilation in controlled mode (Assist Control or SIMV)

Exclusion Criteria:

* Absence of anthropometric data (height and weight) of patients available in the patient file
* Respiratory cycles mainly spontaneous on arrival
* Patient extubated on arrival in intensive care
A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or non-childbearing potential female subjects, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤55 years of age at screening.
* Body mass index \> 18.5 and \< 30.0 kg/m2, and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females at screening visit.
* Capable of consent.

Exclusion Criteria:

* Any clinically significant abnormality or abnormal laboratory test results
* Positive urine drug screen, alcohol breath test, or urine cotinine test
* History of significant allergic reactions to any drug.
* Participation in a clinical research study involving the administration of an investigational or marketed drug or device
* History of clinically significant opportunistic infection
* Presence of fever (body temperature \> 38°C)
Thalidomide to Patients With Previously Untreated Multiple Myeloma

The purpose of this study is to test the effect of thalidomide in patients with multiple myeloma. The patients receive either thalidomide or a placebo tablet (neither patient nor doctor know which of these are given) in addition to the ordinary chemotherapeutic drug against multiple myeloma. We will find out for how long time the patients will stay free of the disease and for how long time they will live, and can evaluate whether thalidomide is a beneficial drug against this disease.

Thalidomide has recently emerged as an effective treatment for patients with myeloma refractory to conventional chemotherapy. So far only limited experience is available on thalidomide for newly diagnosed myeloma. Therefore the Nordic Myeloma Study Group decided to perform a trial comparing traditional melphalan-prednisone therapy with melphalan-prednisone + thalidomide/placebo. The study design is a multicentre double-blind randomised placebo-controlled trial. Mainly patients \>65 years of age will be included since patients \<65 years will be treated with high dose chemotherapy with autologous stem cell support. The primary end-point is overall survival. Secondary end-points are quality of life, response rate, time to response, response duration and toxicity.

Eligibility Criteria:
Inclusion Criteria:

* Patients with multiple myeloma in need of treatment

Exclusion Criteria:

* Previous treatment against multiple myeloma
* Need of high dose chemotherapy with autologous stem cell support
* Women in fertile age
* Psychiatric disease or mental reduction leading to lack of cooperation
* Lack of consent
* Life expectancy below 3 months
* Active cancer of other etiology
Intervention for (Those) Recently Informed of Seropositive Status (IRISS)

An intervention designed to increase positive affect in a population newly diagnosed with HIV will be effective at improving affect and HIV-related outcomes such as mental and physical health, coping and coping resources.

The study is a randomized controlled trial of a 5-session positive affect skills intervention compared to an attention-matched control condition. Participants will be 200 men and women who have tested positive for HIV within the past 12 weeks. Both intervention and control sessions will be approximately one hour long and will be administered one-on-one by trained facilitators. Both groups will have daily home practice over the 5 weeks of the intervention. At the end of the assessment period, participants in the control condition will have the opportunity to attend a ½ day group session that provides a condensed version of the positive affect skills taught in the intervention condition. Participants will complete assessments at four points and CD4 and viral load assays will be run at 3 time points.

Eligibility Criteria:
Inclusion Criteria:

* have been informed they were HIV positive within the past 12 weeks
* speak English or Spanish
* be 18 years or older
* have the ability to provide informed consent to be a research participant.

Exclusion Criteria:

* inability to provide informed consent, as evidenced by cognitive impairment as assessed by trained interviewers and confirmed by a licensed clinical psychologist
* active psychosis as assessed by trained interviewers and confirmed by clinical psychologist
Neurogenic Bladder and Quality of Life in Patients With Stroke

This study investigated effects of the neurogenic bladder on the quality of life in stroke survivors. Patients were divided into two groups: the First group consisted of patients with neurogenic bladder and the Second group consisted of patients without neurogenic bladder.

Neurogenic bladder after stroke is a commonly encountered medical condition which slows down the recovery process and exacerbates the functional status of the patient. The neurogenic bladder may possibly affect the quality of life of patients with stroke.

Objectives: The aim of this study is to investigate the relationship between the quality of life and the neurogenic bladder in Turkish stroke survivors.

Methods: 71 patients with stroke were included in the study. Patients were divided into two groups: the First group consisted of patients with neurogenic bladder and the Second group consisted of patients without neurogenic bladder. Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires were applied to both groups for clinical evaluations.

Eligibility Criteria:
Inclusion Criteria:

* Hemorrhagic or ischemic stroke
* No previous stroke history
* Disease duration \> 6 months

Exclusion Criteria:

* Patients with different stroke etiologies other than cerebrovascular events (such as traumatic and tumoral pathologies)
* Previous multiple stroke history
* Pre-stroke urinary complaints
* Previous urogenital surgery history
* Spinal Cord Injury (SCI)
* Prostate volume of \> 35ml documented with urinary ultrasonography
* Bladder outlet obstruction
* Poorly controlled Diabetes Mellitus (DM)
* Concomitant neurological diseases such as Multiple Sclerosis and Parkinson's Disease
* Anticholinergic, alpha agonist-antagonist drug use
* Sensory and global aphasia
* Severe communication impairment
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.


Eligibility Criteria:
Inclusion Criteria:

* (a) Estimated age ≥ 15 years. Older minimum age is required in some locations. FOR United Kingdom: Estimated or actual age ≥ 16 years FOR Australia: Estimated or actual age ≥ 18 years AND (b) Estimated or actual weight ≥ 50 kg (110 lbs).
* Traumatic injury with confirmed or suspected acute major bleeding and/or Revised Assessment of Bleeding and Transfusion (RABT) score ≥ 2
* Activation of massive transfusion protocol

Exclusion Criteria:

* Healthcare professional cardiopulmonary resuscitation including chest compressions for ≥ 5 consecutive minutes at any time before randomization
* Isolated penetrating or blunt cranial injury, or exposed brain matter
* Isolated burns estimated to be \> 20% total body surface area or suspected inhalational injury
* Known anticoagulation treatment or a history of a TEE, within the past 3 months.
Prebiotics in Peritoneal Dialysis

The Prebiotics in Peritoneal Dialysis trial is a non-randomized, open-label, crossover study of p-inulin for patients with end-stage renal disease treated with peritoneal dialysis.


Eligibility Criteria:
Inclusion Criteria:

* Peritoneal dialysis therapy for end-stage renal disease
* ≥30 days since dialysis initiation
* Ability to provide informed consent

Exclusion Criteria:

* Use of pre- or pro-biotics during the past 2 months
* Consumption of pro-biotic yogurt during the past 2 weeks
* Use of antibiotics within the past 2 months
* Presence of chronic infection
* Chronic gastrointestinal condition other than constipation
* Cirrhosis or chronic active hepatitis
* Stomach/intestinal resection
* PD access problems
* Anticipated kidney transplant or transfer to another dialysis unit within 9 months
* Expected survival \< 9 months
* Pregnancy, anticipated pregnancy, or breastfeeding
* Incarceration
* Participation in another intervention study
* Severe anemia defined as hemoglobin \<9.0 g/dl
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II.

Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.


Eligibility Criteria:
Inclusion Criteria:

* Voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) informed consent/and assent as applicable to participate in the study. Expression of understanding and agreement by fully informed parent(s) or legal guardian is required to permit the investigator to enroll a child in this study. The choice of the terms parental consent or parental permission in different regions may reflect local legal/regulatory and ethical considerations.
* Diagnosis of HAE Type I or Type II.
* Ability to use a mobile device for data collection in the study.

Exclusion Criteria:

* Participation in any interventional clinical trial at the time of enrollment.
* Unable to provide written, signed, and dated informed consent/assent.
* Investigator believes that the participant is not a suitable candidate for the study.
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias

Eligibility Criteria:
Inclusion Criteria:

1. Men and women with a confirmed diagnosis of leukemia unresponsive to curative therapy
2. Eastern Cooperative Oncology Group performance status of 0 to 2
3. Total bilirubin ≤ 1.5 X upper limit of normal (ULN); aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 3 X ULN; serum creatinine ≤ 2 X ULN
4. Normal cardiac function with left ventricular ejection fraction ≥ 50% at screening
5. No clinically significant abnormalities on screening electrocardiogram (ie, QTc interval must be \< 470 msec for women and \< 450 msec for men and no history of torsades de pointes)
6. No reproductive potential or willing to use 2 methods of contraception during the study and for 30 days after the last dose
7. Able to understand the purpose and risks of the study and provide informed consent and authorization to use protected health information

Exclusion Criteria:

1. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral SGI-1776, or put the study outcomes at undue risk
2. Significant cardiovascular disease
3. Malabsorption syndrome
4. Symptomatic central nervous system metastases or lesions for which treatment is required
5. Received prior radiation therapy within 4 weeks of first dose
6. Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation
7. Treatment with any investigational drug within 3 weeks of the first dose
8. Use of systemic corticosteroids (other than for premedications or intermittent doses such as those used for allergic reactions and control of asthma) or myelosuppressive chemotherapy within 2 weeks of the first dose treatment with nitrosoureas or mitomycin C within 3 weeks of the first dose of SGI 1776
9. Uncontrolled active systemic infections
Comparison Between Jacobson's Progressive Muscle Relaxation Technique and Audio-visual Distraction Technique in Reducing Dental Anxiety in Children During Dental Visit

Dental anxiety is fear associated with the thought of visiting the dentist for preventive care and dental procedures. Children with dental anxiety characterized by crying before dental checkup, tachycardia and aggressively clinging to the accompanying parent. It has been cited as the fifthmost common cause of anxiety by Agras et al. Dental anxiety may have major and long-lasting implications for the child and their family. Cohen et al reported that dental anxiety affects an individual's life in multiple ways. The physiological impacts included signs and symptoms of the fright response and feelings of exhaustion after a dental appointment, while the cognitive impacts included an array of negative thoughts, beliefs, and fears. Dental anxiety in children could remain a problem in adulthood if not handled properly thus it will affect oral health and psycho-social condition. This research is conducted to deliver different concepts in psychological and behavioral techniques in management of anxious pediatric dental patients.


Eligibility Criteria:
Inclusion Criteria:

* Children: 6 to 9 years old children. Teeth: tooth requiring dental treatment

Exclusion Criteria:

* Children having allergy to local anaesthesia or systemic problem. Refusal of participation Mentally ill or mentally retarded children
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).


Eligibility Criteria:
Inclusion Criteria:

* Male or Female
* The subject is an out-patient
* Age 30 years or above
* Dyskinesias present during more than 25% of the waking day
* Dyskinesias at least moderately disabling
* Written informed consent

Exclusion Criteria:

* Pregnancy and/or lactation
* Participation in another study within the last 30 days
* Dementia or other psychiatric illness that prevents provision of informed consent
* History of allergic disorders such as asthma
* Known hypersensitivity to the study treatment(s)
* Known hypersensitivity to ACTH